Business Wire

Outseer Launches Platformized Behavioral Biometrics Delivering Unmatched Defense in Depth

Share

Leader in Authentication and Fraud Prevention Natively Incorporates Behavioral Biometric Signals into AI-Powered Platform

Outseer, a recognized leader in authentication and fraud prevention for digital banking and 3-D Secure (3DS) transactions, announced its platform-native Behavioral Biometrics capability today. The addition of platformized Behavioral Biometrics introduces another layer of defense that continuously analyzes user interactions to detect anomalies in real time. Building on its rich RSA® heritage (formerly RSA Fraud & Risk Intelligence™), Outseer has enhanced its platform to meet today’s dynamic threat landscape. As fraud evolves—spurred by the digitization of payments, the spread of personal data across the dark web, the growing threat of scams and authorized fraud, as well as advancements like GenAI—Outseer’s multi-signal risk engine, leveraging sophisticated machine learning algorithms and AI, sets a new standard for continuous, unified protection.

“Our customers are facing rising authorized and unauthorized fraud threats in digital banking and 3DS transactions, requiring fraud solutions that can accurately distinguish genuine users and transactions from criminal activity,” said John Filby, CEO of Outseer. “The key to our innovations, from Behavioral Biometrics, Fast Identity Online (FIDO) authentication orchestration, and money mule modeling, to GenAI-based adaptive interventions, is developing them in close collaboration with our clients. Thanks to these innovations and platform-native componentry, we are addressing all-cause fraud and regulatory requirements with superior accuracy, scalability, and deployability.”

Outseer’s new, best-in-class Behavioral Biometric capability, delivers enhanced authentication coupled with advanced criminal pattern recognition—ensuring regulatory compliance and improved fraud detection for difficult-to-spot fraudster techniques. By correlating behavioral insights with other contextual fraud signals, the Outseer platform delivers superior fraud detection while minimizing friction for legitimate users—more signal and less noise. Outseer has developed and incorporated this within its unified fraud platform to ensure a seamless enablement without the additional integration, vendor compliance, and contractual complexity necessitated by third-party point solutions.

“Defense in depth remains the gold standard in the fight against fraud, and our platformized approach is the only way to achieve it at scale,” added Dr. Yogesh Patel, CTO and Chief Data Scientist at Outseer. “Our AI-powered platform ingests the full spectrum of critical fraud signals, including event data, device IDs, geo-IP, consortium data, and now Behavioral Biometrics. Our commitment to platform-native, client-centric solutions is transforming how fraud is detected as we fulfill our mission to make the world a safer place.”

About Outseer

Outseer is a leader in authentication and fraud prevention, delivering defense in depth through a uniquely comprehensive platform that protects digital banking sessions and 3DS transactions. With our rich RSA® heritage and an unwavering commitment to innovation, Outseer’s AI-powered platform incorporates a spectrum of critical fraud signals, including event data, device IDs, geo-IP, Behavioral Biometrics, consortium data, and more. Trusted by thousands of clients in over 50 countries, including hundreds of the world’s largest financial institutions, Outseer solutions safeguard more than 450 million accounts, 100 billion transactions, and 5 trillion dollars annually.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250318668335/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SBC Medical added to membership of Russell 3000® Index28.6.2025 01:30:00 CEST | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global franchise and provider of services for aesthetic clinics, has been added as a member of the broad-market Russell 3000® Index, effective after the US market opens on June 30, as part of the 2025 Russell indexes reconstitution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250608244276/en/ Yoshiyuki Aikawa-Director (Chairman), CEO Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000®Index as well as the appropriate growth and value style indexes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to

Altimetrik and SLK Software Join Forces to Create an AI-First Engineering Services Powerhouse27.6.2025 22:44:00 CEST | Press release

Altimetrik, a pure-play AI, Data and Digital engineering solutions company, today announced the signing of a definitive agreement to acquire SLK Software (“SLK”), a global technology services firm focused on delivering AI, intelligence automation and analytics solutions. The acquisition will further strengthen Altimetrik’s end-to-end enablement services and expand its customer reach, with a clear path to accelerate towards Altimetrik’s goal of reaching $1billion in annual revenue. The transaction remains subject to customary closing conditions and is expected to close in the second half of 2025. Financial details were not disclosed. Founded in 2000, SLK is recognized as a leader in the tech industry, and for its commitment to create innovative digital solutions. This strategic acquisition will significantly enhance the scale of Altimetrik’s capabilities, bringing together Altimetrik’s AI-first, platform-native engineering model and SLK’s full technology services stack that will further

Andersen Consulting udvider sine kompetencer inden for forretningstransformation med tilføjelsen af The Clearing27.6.2025 16:48:00 CEST | Pressemeddelelse

Andersen Consulting udbygger sin platform med samarbejdsfirmaet The Clearing, som er en managementkonsulentvirksomhed med speciale i organisatorisk omstilling og lederudvikling. The Clearing blev stiftet i 2009 og rådgiver kunder om komplekse udfordringer ved at afstemme ledelse, strategi, kultur og drift. Firmaet arbejder med føderale agenturer, virksomheder og nonprofitorganisationer med henblik på at skabe målbare forandringer på tværs af forskellige interessenter til gavn for en leders vision og strategi. Med dyb erfaring inden for flere sektorer, herunder national sikkerhed, sundhedspleje og finansielle tjenester, leder The Clearings unikke blanding af talent med ekspertise inden for organisationsudvikling, dataanalyse og visuel rådgivning forretningstransformationer i stor skala og arbejder sammen med kunder og eksperter for at sikre, at rådgivning omsættes til implementering. "Vi leverer transformative resultater, der ikke kun er i overensstemmelse med strategiske mål, men også

PRD Therapeutics Announces Initiation of First-in-Human Study for PRD00127.6.2025 16:00:00 CEST | Press release

PRD Therapeutics, Inc., a clinical stage company focused on the development of novel lipid metabolism regulators targeting homozygous familial hypercholesterolemia (HoFH) and metabolic dysfunction associated fatty liver disease (MASH/MASLD), today announced that the company recently initiated dosing in a First-in-Human (FIH) clinical trial of PRD001, a first-in-class SOAT2 (formerly known as ACAT2) selective inhibitor. “We are excited to initiate dosing in this clinical trial of PRD001. Many clinical trials have been conducted on SOAT1/2 dual or SOAT1 selective inhibitors, but this is the first clinical trial of an SOAT2 selective inhibitor” said Kanji Hosoda, Ph.D., CEO and co-founder of PRD Therapeutics. “Several results with SOAT1 or 2 knockout mice have been published, suggesting that knocking out or inhibiting only SOAT2 is crucial to demonstrate safety and efficacy. PRD001 is the world's first and only SOAT2-selective inhibitor and is expected to exhibit safety and efficacy in hu

STEMCELL Technologies Introduces STEMprep™ Tissue Dissociator System to Accelerate Research Discoveries27.6.2025 14:00:00 CEST | Press release

New instrument automates tissue processing for researchers in cancer, immunology and other science fields To help scientists accelerate their workflows, STEMCELL Technologies has commercially launched the STEMprep™ Tissue Dissociator System—a new benchtop instrument that automates, standardizes, and streamlines tissue dissociation, the process of breaking down tissue samples into single-cell suspensions for research purposes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250627342791/en/ To help scientists accelerate their workflows, STEMCELL Technologies has commercially launched the STEMprep™ Tissue Dissociator System—a new benchtop instrument that automates, standardizes, and streamlines tissue dissociation, the process of breaking down tissue samples into single-cell suspensions for research purposes. “Tissue dissociation is incredibly important for making advancements in research fields, like cancer and immunology, yet

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye